INNATE PHARMA SA-SPONS ADR (IPHA) Stock Fundamental Analysis

NASDAQ:IPHA • US45781K2042

1.62 USD
-0.09 (-5.54%)
Last: Mar 3, 2026, 03:56 PM
Fundamental Rating

2

IPHA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 520 industry peers in the Biotechnology industry. IPHA has a bad profitability rating. Also its financial health evaluation is rather negative. IPHA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • IPHA had negative earnings in the past year.
  • In the past year IPHA has reported a negative cash flow from operations.
  • IPHA had negative earnings in each of the past 5 years.
  • IPHA had a negative operating cash flow in each of the past 5 years.
IPHA Yearly Net Income VS EBIT VS OCF VS FCFIPHA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -49.55%, IPHA perfoms like the industry average, outperforming 50.19% of the companies in the same industry.
  • IPHA has a worse Return On Equity (-895.24%) than 79.23% of its industry peers.
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROIC N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
IPHA Yearly ROA, ROE, ROICIPHA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

  • With a decent Gross Margin value of 49.52%, IPHA is doing good in the industry, outperforming 75.38% of the companies in the same industry.
  • IPHA's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for IPHA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
IPHA Yearly Profit, Operating, Gross MarginsIPHA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

2

2. Health

2.1 Basic Checks

  • IPHA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IPHA has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for IPHA has been increased compared to 5 years ago.
  • Compared to 1 year ago, IPHA has an improved debt to assets ratio.
IPHA Yearly Shares OutstandingIPHA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
IPHA Yearly Total Debt VS Total AssetsIPHA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • Based on the Altman-Z score of -6.50, we must say that IPHA is in the distress zone and has some risk of bankruptcy.
  • IPHA has a Altman-Z score of -6.50. This is in the lower half of the industry: IPHA underperforms 64.81% of its industry peers.
  • A Debt/Equity ratio of 3.52 is on the high side and indicates that IPHA has dependencies on debt financing.
  • IPHA's Debt to Equity ratio of 3.52 is on the low side compared to the rest of the industry. IPHA is outperformed by 80.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Altman-Z -6.5
ROIC/WACCN/A
WACC7.02%
IPHA Yearly LT Debt VS Equity VS FCFIPHA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • IPHA has a Current Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
  • IPHA has a Current ratio of 2.21. This is in the lower half of the industry: IPHA underperforms 74.23% of its industry peers.
  • IPHA has a Quick Ratio of 2.21. This indicates that IPHA is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.21, IPHA is not doing good in the industry: 72.12% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.21
Quick Ratio 2.21
IPHA Yearly Current Assets VS Current LiabilitesIPHA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

3

3. Growth

3.1 Past

  • IPHA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.42%.
  • IPHA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -75.86%.
  • IPHA shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -28.80% yearly.
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%

3.2 Future

  • IPHA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -19.15% yearly.
  • Based on estimates for the next years, IPHA will show a very strong growth in Revenue. The Revenue will grow by 41.95% on average per year.
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IPHA Yearly Revenue VS EstimatesIPHA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M
IPHA Yearly EPS VS EstimatesIPHA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -0.2 -0.4 -0.6

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for IPHA. In the last year negative earnings were reported.
  • Also next year IPHA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IPHA Price Earnings VS Forward Price EarningsIPHA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IPHA Per share dataIPHA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

  • A cheap valuation may be justified as IPHA's earnings are expected to decrease with -19.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%

0

5. Dividend

5.1 Amount

  • No dividends for IPHA!.
Industry RankSector Rank
Dividend Yield 0%

INNATE PHARMA SA-SPONS ADR

NASDAQ:IPHA (3/3/2026, 3:56:05 PM)

1.62

-0.09 (-5.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-26
Inst Owners9.46%
Inst Owner Change238.5%
Ins Owners0.92%
Ins Owner ChangeN/A
Market Cap151.80M
Revenue(TTM)6.00M
Net Income(TTM)-46.05M
Analysts82.5
Price Target7.41 (357.41%)
Short Float %0.19%
Short Ratio5.56
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.68%
PT rev (3m)30.64%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)1.64%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)4.93%
Revenue NY rev (3m)4.93%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.63
P/FCF N/A
P/OCF N/A
P/B 25.23
P/tB 25.23
EV/EBITDA N/A
EPS(TTM)-0.6
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.52
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS0.07
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.55%
ROE -895.24%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.52%
FCFM N/A
ROA(3y)-25.54%
ROA(5y)-23.43%
ROE(3y)-227.3%
ROE(5y)-154.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.49%
GM growth 5Y-4.49%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 3.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.84%
Cap/Sales 2.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.21
Quick Ratio 2.21
Altman-Z -6.5
F-Score2
WACC7.02%
ROIC/WACCN/A
Cap/Depr(3y)22.77%
Cap/Depr(5y)23.45%
Cap/Sales(3y)3.3%
Cap/Sales(5y)8.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.82%
EPS Next Y-35.8%
EPS Next 2Y-10.55%
EPS Next 3Y-19.15%
EPS Next 5YN/A
Revenue 1Y (TTM)-75.86%
Revenue growth 3Y1.38%
Revenue growth 5Y-28.8%
Sales Q2Q%-79.85%
Revenue Next Year-22.57%
Revenue Next 2Y-12.86%
Revenue Next 3Y-22.02%
Revenue Next 5Y41.95%
EBIT growth 1Y-31.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year177.82%
EBIT Next 3Y95.79%
EBIT Next 5YN/A
FCF growth 1Y-27.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.01%
OCF growth 3YN/A
OCF growth 5YN/A

INNATE PHARMA SA-SPONS ADR / IPHA FAQ

What is the ChartMill fundamental rating of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to IPHA.


Can you provide the valuation status for INNATE PHARMA SA-SPONS ADR?

ChartMill assigns a valuation rating of 0 / 10 to INNATE PHARMA SA-SPONS ADR (IPHA). This can be considered as Overvalued.


What is the profitability of IPHA stock?

INNATE PHARMA SA-SPONS ADR (IPHA) has a profitability rating of 1 / 10.


What is the financial health of INNATE PHARMA SA-SPONS ADR (IPHA) stock?

The financial health rating of INNATE PHARMA SA-SPONS ADR (IPHA) is 2 / 10.